TCnet:一种新的策略,通过基于网络的方法预测阿尔茨海默病的目标组合
Chengyuan Yue1, Baiyu Chen1, Fei Pan1
1Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Journal of chemical information and modeling
|April 2, 2025
概括
这项研究介绍了TCnet,这是一种使用多组数据治疗阿尔茨海默病 (AD) 的新型多目标治疗方法. 它通过预测AD治疗的最佳标组合来确定奎尔素作为潜在的候选药物.
科学领域:
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的发病因子尚不清楚,限制了单一向药物的疗效.
- 由于疾病的复杂性,AD的传统治疗策略是不够的.
研究的目的:
- 通过整合多组学数据和网络分析,开发一种新的多目标治疗策略.
- 为了确定最佳的药物标组合,并选潜在的治疗化合物用于AD.
主要方法:
- 使用了一种机制驱动的策略 (TCnet),集成多组数据来进行疾病机制分解.
- 采用网络分析来构建和优先考虑潜在的药物目标组合.
- 通过TCnet方法选来自黄莲杰杜唐 (HLJDT) 的活性化合物.
主要成果:
- 鉴定了氨酸作为一种候选向GSK3β和ADAM17的AD治疗药物.
- 通过"体外实验"实验证实了奎尔塞的神经保护和抗炎作用.
- TCnet提高了对AD机制的理解,并促进了药物查.
结论:
- 在AD药物发现中,TCnet提供了一种有前途的方法来预测多目标组合.
- 这项研究为开发有效的AD疗法提供了新的见解和方向.
更多相关视频
14:27Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
15.6K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
相关概念视频
01:26Alzheimer's Disease: Overview
350
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
350
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133